Correale, Jorge published the artcileBruton’s tyrosine kinase inhibitors as potential therapies for multiple sclerosis, Computed Properties of 1971920-73-6, the publication is Lancet Neurology (2021), 20(9), 689-691, database is CAplus and MEDLINE.
A review. Over the past 30 years increasing numbers of mols. have been developed for treatment of multiple sclerosis. Bruton’s tyrosine kinase is a cytoplasmic tyrosine kinase expressed by B cells and myeloid cells. Both B cells and myeloid cells (particularly microglia) are important drivers of multiple sclerosis, suggesting that inhibitors of Bruton’s tyrosine kinase, such as the irreversible inhibitors evobrutinib, tolebrutininb, and orelabrutinib, and the reversible inhibitors fenebrutinib and BIIB091, might provide therapeutic benefits for patients. Bruton’s tyrosine kinase inhibitors could provide attractive therapeutic benefits for patients with multiple sclerosis, with potential advantages over monoclonal antibodies because they might be less likely to trigger antibody responses, allergic reactions,or neutralisation of their therapeutic actions. Addnl., these inhibitors, as small mols., might be able to access the CNS and inhibit microglial activation. However, whether Bruton’s tyrosine kinase inhibitors will be more efficacious than monoclonal antibodies remains to be established.
Lancet Neurology published new progress about 1971920-73-6. 1971920-73-6 belongs to piperidines, auxiliary class Other Aliphatic Heterocyclic,Piperidine,Alkenyl,Amine,Benzene,Ether,Inhibitor,Inhibitor, name is (R)-1-(1-Acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one, and the molecular formula is C26H25N5O3, Computed Properties of 1971920-73-6.
Referemce:
https://en.wikipedia.org/wiki/Piperidine,
Piperidine | C5H11N – PubChem